Mode
Text Size
Log in / Sign up
N/A N=6 Treatment

Early-Phase Safety of Proton Therapy Equipment

Malignant Glioma · Hepatocellular Carcinoma · Head and Neck Malignant Tumor · Prostate Cancer

Enrolled (actual)
6
Serious AEs
0.0%
Results posted
Dec 2015
Primary outcome: Primary: Rate and Severity of Adverse Reactions — 6 participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
proton therapy (Radiation)
Age
Adult, Older Adult · 20+ yrs
Sex
All
Sponsor
Chang Gung Memorial Hospital
Primary completion
Feb 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Rate and Severity of Adverse Reactions
6
SECONDARY
Percentage of System Errors
12.7
SECONDARY
Percentage of Each Target Lesion Evaluation Types.(1)Complete Response(2)Partial Response,(3)Progressive Disease,(4)Stable Disease,(5) Inevaluable
50; 16.67; 33.33

Summary

The main purpose of this study is to collect the safety data of Sumitomo Heavy Industries' proton therapy equipment for the treatment of solid cancer patients in Linkou Chang Gung Memorial Hospital, including the patients' early-stage adverse reactions and the efficacy on tumors, as well as to assess the operating functionality of the proton therapy system.

Eligibility Criteria

Inclusion Criteria

  • Subjects who are pathologically confirmed to be suffering from solid cancer or brain tumor
  • Subjects who are measurable or with disease that is evaluable
  • Subjects who are expected to survive for at least 90 days
  • Subjects who did not receive any treatment that may affect this treatment (such as PEI, TAE) 4 weeks before they are chosen to receive this treatment
  • ECOG Performance Status (ECOG PS): 0, 1 or 2
  • Patients who can cooperate with the treatment requirements and maintain the gestures required during the irradiation process
  • Patients with well functioning main organs
  • The subject retained main organ functions.
  • The subject age is between 20-75 years old

Exclusion Criteria

  • Subjects who once received radiotherapy on the area planned to be irradiated
  • Subjects whose irradiated area has active or persistent infectious disease
  • Pregnant or possibly pregnant subjects
  • Subjects with other serious complications
  • Subjects who are judged by the Principle Investigator (or co-principle investigator) as unsuitable or because of other reasons described above
  • The subject has the radiotherapy contraindication
  • Breast feeding
  • All the subjects have no plan to conception during the treatment and within one year after treatment
  • Subject who has any electronic devices in the body which could be affected by radiotherapy and has chance to cause accident. For example: pacemaker, artificial heart, brain and spinal cord stimulation, semi-implantable and implantable electrical stimulation、artificial inner ear ...etc
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02315989). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search